Table 2.
Patient and tumor characteristics of MIBC patients who received neoadjuvant chemotherapy.
| Patient characteristics | MIBC patients with NAC | |
|---|---|---|
| Total n = 32, (%) | ||
| Follow‐up duration | Mean ± SD | 46.0 ± 9.35 |
| Time to death | Mean ± SD | 14.1 ± 4.6 |
| Time to meta | Mean ± SD | 33.4 ± 4.21 |
| Age | < 75 | 24 (75.0) |
| ≥ 75 | 8 (25.0) | |
| Sex | Male | 25 (78.1) |
| Female | 7 (21.9) | |
| ECOG‐PS | 0–1 | 29 (90.6) |
| 2 | 3 (9.4) | |
| Tumor histology | Pure UC | 27 (84.4) |
| Non‐pure UC | 5 (15.6) | |
| Pathological T stage | T0 | 11 (34.4) |
| 1 | 4 (12.5) | |
| 2 | 7 (21.9) | |
| 3 | 6 (18.7) | |
| 4 | 4 (12.5) | |
| Pathological N stage | 0 | 24 (75.0) |
| 1,2 | 8 (25.0) | |
| Tumor grade | Low | 2 (6.2) |
| High | 30 (93.8) | |
| LVI | Absent | 18 (56.2) |
| Present | 14 (43.8) | |
| Concomitant CIS | No | 29 (90.6) |
| Yes | 3 (9.4) | |
| Systemic adjuvant chemotherapy | No | 25 (78.1) |
| Yes | 7 (21.9) | |
| Tumor recurrence | No | 18 (56.2) |
| Yes | 14 (43.8) | |
| Cancer specific death | No | 19 (59.4) |
| Yes | 13 (40.6) |
CIS; carcinoma in situ; ECOG‐PS; Eastern Cooperative Oncology Group‐ Performance Status; LVI; lymphovascular invasion; MIBC; muscle invasive bladder cancer; NAC; neoadjuvant chemotherapy; SD; standard deviation; UC; urothelial carcinoma.